$TNXP News

Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline

Tonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript

Tonix Pharmaceuticals Holding Corp. 2026 Q2 - Results - Earnings Call Presentation

Tonix Delivers A Beat, But The Real Test Starts Now

Tonix Pharmaceuticals Holding Corp (TNXP) (Q2 2026) Earnings Call Highlights: TONMYA Surges ...

Tonix Pharmaceuticals Q2 Earnings Call Highlights

Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript

Tonix Pharmaceuticals Q2 EPS $(2.44) Beats $(2.64) Estimate, Sales $13.544M Beat $7.723M Estimate

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.

Tonix Pharma Receives Official Minutes From Type C Meeting With FDA To Discuss Plans For Adaptive Phase 2 Field Study Of TNX-4800 To Prevent Lyme Disease In Adults In US

Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026

Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models

Tonix Pharma Announces Publication Of Monkeypox Study In Journal Of Virology, Peer-Reviewed Publication Of ASM

Tonix Expands TONMYA Medicare Coverage with New Payer Agreement (TNXP)

Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®

Tonix Secures Medicare Coverage For Fibromyalgia Drug TONMYA, Expands TONMYA Coverage To 145M Lives By 2027

Tonix: 'Hold' Based On Tonmya Payer Expansions And MDD Trial Initiation

Tonix: Slow Start For Tonmya, Speculative Pipeline Warrants Hold Rating

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)